MedTrace Logo

Oral Chemotherapeutic Drugs Were Analyzed in Patients With Driver Gene Negative Locally Advanced/Advanced Non-small Cell Lung Cancer With PS Score 2 A Prospective, Single-arm, Multicenter, Observational Study on the Efficacy and Safety of Radiochemotherapy Combined With PD-1 Inhibitor

NCT06310915 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2024-03-15

No results posted yet for this study

Summary

Oral chemotherapeutic drugs were analyzed in patients with driver gene negative locally advanced/advanced non-small cell lung cancer with PS score 2 A prospective, single-arm, multicenter, observational study on the efficacy and safety of radiochemotherapy combined with PD-1 inhibitor.

Conditions

  • Non-small Cell Lung Cancer Stage IIIB/IV

Interventions

DRUG

Navelbine oral,Pembrolizumab

Oral vinorelbine was administered three times weekly, and pembrolizumab was administered every 3 weeks

Sponsors & Collaborators

  • Guangzhou Institute of Respiratory Disease

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-17
Primary Completion
2025-03-31
Completion
2025-05-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06310915 on ClinicalTrials.gov